Kojonazarov, Baktybek, Jainagul Isakova, Baktybek Imanov, Nurmira Sovkhozova, Talantbek Sooronbaev, Takeshi Ishizaki, and Almaz A. Aldashev. Bosentan reduces pulmonary artery pressure in high altitude residents. High Alt Med Biol. 13:217–223, 2012.—Endothelin-1 (ET-1) plays a critical role in the regulation of pulmonary vascular tone. The aim of this study was to investigate the role of ET-1 in the pathogenesis of high altitude pulmonary arterial hypertension (HAPH). Methods: Pulmonary artery pressure (PAP) was measured by echocardiography in permanent residents of the Kyrgyz Republic (3200–4000 m above sea level) both before and 3 h after a single oral dose of ET receptor antagonist, bosentan (125 mg). Plasma ET-1 levels were measured by ELISA assay. Genomic DNA was extracted from peripheral blood samples and the frequency of -3a and -4a alleles of the ET-1 gene determined by PCR. Results: Plasma ET-1 in HAPH highlanders was significantly higher than in healthy subjects (7.05±2.35 vs. 4.65±1.65 pg/ml, p<0.002). After the treatment with 125 mg bosentan, systolic PAP decreased from 46±1.9 to 37±2.2 mm Hg (p<0.01), and pulmonary artery acceleration time (PAAT) increased from 0.086±0.001 to 0.098±0.001 sec (p<0.001). The frequency of the -4a allele was significantly higher in HAPH patients compared to healthy highlanders (0.43 vs. 0.3, χ2=4.3, p=0.03). Conclusion: Increased ET-1 levels play an important role in development of HAPH.
Get full access to this article
View all access options for this article.
References
1.
AldashevAA. 2000. High-altitude pulmonary hypertension and signal transduction in the cardiovascular system. J Receptor Signal Transduc Res, 20:255–278.
2.
AldashevAA, SarybaevAS, SydykovAS, KalmyrzaevBB, KimEV, MamanovaLB, MaripovR, KojonazarovBK, MirrakhimovMM, WilkinsMR, MorrellNW. 2002. Characterization of high-altitude pulmonary hypertension in the Kyrgyz: Association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med, 166:1396–1402.
3.
AldashevAA, KojonazarovBK, AmatovTA, SooronbaevTM, MirrakhimovMM, MorrellNW, WhartonJ, WilkinsMR. 2005. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax, 60:683–687.
4.
Arias-StellaJ, SaldanaM. 1963. The terminal portion of the pulmonary arterial tree in people native to high altitudes. Circulation, 28:915–925.
5.
CacoubP, DorentR, NatafP, CarayonA, RiquetM, NoeE, PietteJC, GodeauP, GandjbakhchI. 1997. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res, 33:196–200.
6.
ChannickRN, SimonneauG, SitbonO, RobbinsIM, FrostA, TapsonVF, BadeschDB, RouxS, RainisioM, BodinF, RubinLJ. 2001. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet, 358:1119–1123.
7.
ChowLC, DittrichHC, HoitBD, MoserKM, NicodPH. 1988. Doppler assessment of changes in right-sided cardiac hemodynamics after pulmonary thromboendarterectomy. Am J Cardiol, 61:1092–1097.
8.
DromaY, HayanoT, TakabayashiY, KoizumiT, KuboK, KobayashiT, SekiguchiM. 1996. Endothelin-1 and interleukin-8 in high altitude pulmonary oedema. Eur Respir J, 9:1947–1949.
9.
DromaY, HanaokaM, OtaM, KatsuyamaY, KoizumiT, FujimotoK, KobayashiT, KuboK. 2002. Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-altitude pulmonary edema. Circulation, 106:826–830.
10.
DromaY, HanaokaM, BasnyatB, ArjyalA, NeupaneP, PanditA, SharmaD, MiwaN, ItoM, KatsuyamaY, OtaM, KuboK. 2006. Genetic contribution of the endothelial nitric oxide synthase gene to high altitude adaptation in sherpas. High Alt Med Biol, 7:209–220.
GiaidA, YanagisawaM, LanglebenD, MichelRP, LevyR, ShennibH, KimuraS, MasakiT, DuguidWP, StewartDJ. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl J Med, 328:1732–1739.
13.
GoerreS, WenkM, BartschP, LuscherTF, NiroomandF, HohenhausE, OelzO, ReinhartWH. 1995. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation, 91:359–364.
14.
GroverRF, VogelJH, VoigtGC, BlountSGJr. 1966. Reversal of high altitude pulmonary hypertension. Am J Cardiol, 18:928–932.
HumbertM, MorrellNW, ArcherSL, StenmarkKR, MacLeanMR, LangIM, ChristmanBW, WeirEK, EickelbergO, VoelkelNF, RabinovitchM. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol, 43:13S–24S.
17.
KitabatakeA, InoueM, AsaoM, MasuyamaT, TanouchiJ, MoritaT, MishimaM, UematsuM, ShimazuT, HoriM, AbeH. 1983. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation, 68:302–309.
18.
KojonazarovBK, ImanovBZ, AmatovTA, MirrakhimovMM, NaeijeR, WilkinsMR, AldashevAA. 2007. Noninvasive and invasive evaluation of pulmonary arterial pressure in highlanders. Eur Respir J, 29:352–356.
19.
KosturakisD, GoldbergSJ, AllenHD, LoeberC. 1984. Doppler echocardiographic prediction of pulmonary arterial hypertension in congenital heart disease. Am J Cardiol, 53:1110–1115.
20.
Leon-VelardeF, MaggioriniM, ReevesJT, AldashevA, AsmusI, BernardiL, GeRL, HackettP, KobayashiT, MooreLG, PenalozaD, RichaletJP, RoachR, WuT, VargasE, Zubieta-CastilloG, Zubieta-CallejaG. 2005. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol, 6:147–157.
21.
LiH, EltonTS, ChenYF, OparilS. 1994. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol, 266:L553–560.
22.
MacLeanMR. 1998. Endothelin-1: A mediator of pulmonary hypertension?Pulmon Pharmacol Therap, 11:125–132.
23.
ModestiPA, VanniS, MorabitoM, ModestiA, MarchettaM, GamberiT, SofiF, SaviaG, ManciaG, GensiniGF, ParatiG. 2006. Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) Study. Circulation, 114:1410–1416.
24.
MorrellNW, SarybaevAS, AlikhanA, MirrakhimovMM, AldashevAA. 1999. ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders. Lancet, 353:814.
25.
NootensM, KaufmannE, RectorT, ToherC, JuddD, FrancisGS, RichS. 1995. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol, 26:1581–1585.
26.
OlfertIM, LoeckingerA, TremlB, FaulhaberM, FlatzM, BurtscherM, TruebsbachS, KleinsasserA. 2011. Sildenafil and bosentan improve arterial oxygenation during acute hypoxic exercise: A controlled laboratory trial. Wilderness Environ Med, 22:211–221.
27.
PenalozaD, SimeF. 1971. Chronic cor pulmonale due to loss of altitude acclimatization (chronic mountain sickness)Am J Med, 50:728–743.
28.
PhamI, WuerznerG, RichaletJP, PeyrardS, AziziM. 2010. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans. Eur J Clin Invest, 40:195–202.
29.
RajputC, NajibS, NorbooT, AfrinF, Qadar PashaMA. 2006. Endothelin-1 gene variants and levels associate with adaptation to hypobaric hypoxia in high-altitude natives. Biochem Biophys Res Commun, 341:1218–1224.
SeheultRD, RuhK, FosterGP, AnholmJD. 2009. Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. Respir Physiol Neurobiol, 165:123–130.
33.
ShirakamiG, NakaoK, SaitoY, MagaribuchiT, JougasakiM, MukoyamaM, AraiH, HosodaK, SugaS, OgawaYet al.1991. Acute pulmonary alveolar hypoxia increases lung and plasma endothelin-1 levels in conscious rats. Life Sci, 48:969–976.
34.
StewartDJ, LevyRD, CernacekP, LanglebenD. 1991. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?Ann Int Med, 114:464–469.
35.
TanakaC, KamideK, TakiuchiS, KawanoY, MiyataT. 2004. Evaluation of the Lys198Asn and −134delA genetic polymorphisms of the endothelin-1 gene. Hyperten Res, 27:367–371.
36.
VaskuA, SpinarovaL, GoldbergovaM, MuzikJ, SpinarJ, VitovecJ, TomanJ, VachaJ. 2002. The double heterozygote of two endothelin-1 gene polymorphisms (G8002A and −3A/-4A) is related to big endothelin levels in chronic heart failure. Exp Mol Pathol, 73:230–233.
37.
WagnerOF, VierhapperH, GasicS, NowotnyP, WaldhauslW. 1992. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest, 22:277–282.
38.
WeirEK, TuckerA, ReevesJT, WillDH, GroverRF. 1974. The genetic factor influencing pulmonary hypertension in cattle at high altitude. Cardiovasc Res, 8:745–749.
39.
WestcottRN, FowlerNO, ScottRC, HauensteinVD, McGJ. 1951. Anoxia and human pulmonary vascular resistance. J Clin Invest, 30:957–970.
40.
WhitmanEM, PisarcikS, LukeT, FallonM, WangJ, SylvesterJT, SemenzaGL, ShimodaLA. 2008. Endothelin-1 mediates hypoxia-induced inhibition of voltage-gated K+ channel expression in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol, 294:L309–318.
41.
YanagisawaM, MasakiT. 1989. Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Pharmacol, 38:1877–1883.
42.
YangX, ChenW, ChenJ. 1997. Change of level and expression of endothelin-1 in the lungs of rats with hypoxic pulmonary hypertension. Chinese Med J, 110:104–108.
43.
YockPG, PoppRL. 1984. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation, 70:657–662.
